Tag: Soluble guanylate cyclase

First approved by the FDA in 2013, Adempas (riociguat) is a unique medication that was the first in a new class of drugs for pulmonary hypertension. It is prescribed to treat two specific types of pulmonary hypertension in adults, and for pediatric patients of a certain weight with pulmonary arterial hypertension (PAH).

Adempas (riociguat) was the first member of a new drug class known as soluble guanylate cyclase (sGC) stimulators to receive FDA approval in 2013. This medication is used to treat adults with two specific types of high blood pressure in the lungs: chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).